NasdaqGS - Nasdaq Real Time Price
USD
BridgeBio Pharma, Inc. (BBIO)
74.37
-1.04
(-1.38%)
As of 3:26:45 PM EDT. Market Open.
Trade BBIO on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for BBIO
- Previous Close
75.41 - Open
74.98 - Bid 68.96 x 200
- Ask 80.09 x 200
- Day's Range
74.11 - 75.36 - 52 Week Range
48.78 - 93.42 - Volume
890,283 - Avg. Volume
3,031,353 - Market Cap (intraday)
14.539B - Beta (5Y Monthly) 0.97
- PE Ratio (TTM)
-- - EPS (TTM)
-3.56 - Earnings Date (est.) Oct 28, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
109.10
Recent News
View More
Performance Overview
Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
BBIO
2.77%
S&P 500 (^GSPC)
12.69%
1-Year Return
BBIO
43.49%
S&P 500 (^GSPC)
18.64%
3-Year Return
BBIO
143.20%
S&P 500 (^GSPC)
70.83%
5-Year Return
BBIO
44.07%
S&P 500 (^GSPC)
70.09%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 9/1/2026
-
Market Cap
14.97B
-
Enterprise Value
16.74B
-
Trailing P/E
--
-
Forward P/E
--
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
20.83
-
Price/Book (mrq)
--
-
Enterprise Value/Revenue
23.48
-
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
-
Profit Margin
-97.03%
-
Return on Assets (ttm)
-26.00%
-
Return on Equity (ttm)
--
-
Revenue (ttm)
713.07M
-
Net Income Avi to Common (ttm)
-691.87M
-
Diluted EPS (ttm)
-3.56
Balance Sheet and Cash Flow
-
Total Cash (mrq)
720.16M
-
Total Debt/Equity (mrq)
--
-
Levered Free Cash Flow (ttm)
-320.26M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
BridgeBio Earnings: Strong Attruby Uptake as Late-Stage Candidates Are Under Regulatory Review
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
RatingPrice Target -
BridgeBio Earnings: Strong Sales of Attruby and Advancing Pipeline Support Positive Outlook
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
RatingPrice Target -
BridgeBio Earnings: Strong Sales of Attruby and Advancing Pipeline Support Positive Outlook
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
RatingPrice Target -
BridgeBio Earnings: Strong Sales of Attruby and Advancing Pipeline Support Positive Outlook
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
RatingPrice Target
